HRP20170001T1 - Nove podgrupe pacijenata za trombolizu - Google Patents
Nove podgrupe pacijenata za trombolizu Download PDFInfo
- Publication number
- HRP20170001T1 HRP20170001T1 HRP20170001TT HRP20170001T HRP20170001T1 HR P20170001 T1 HRP20170001 T1 HR P20170001T1 HR P20170001T T HRP20170001T T HR P20170001TT HR P20170001 T HRP20170001 T HR P20170001T HR P20170001 T1 HRP20170001 T1 HR P20170001T1
- Authority
- HR
- Croatia
- Prior art keywords
- desmoteplase
- patient
- use according
- stroke
- cerebral
- Prior art date
Links
- 230000002537 thrombolytic effect Effects 0.000 title 1
- 108010057987 Desmodus rotundus salivary plasminogen activator alpha 1 Proteins 0.000 claims 10
- 229950001282 desmoteplase Drugs 0.000 claims 10
- 208000006011 Stroke Diseases 0.000 claims 9
- 206010008089 Cerebral artery occlusion Diseases 0.000 claims 3
- 208000031481 Pathologic Constriction Diseases 0.000 claims 3
- 230000036262 stenosis Effects 0.000 claims 3
- 208000037804 stenosis Diseases 0.000 claims 3
- 208000031104 Arterial Occlusive disease Diseases 0.000 claims 2
- 208000021328 arterial occlusion Diseases 0.000 claims 2
- 230000037396 body weight Effects 0.000 claims 2
- 230000001010 compromised effect Effects 0.000 claims 2
- 206010061216 Infarction Diseases 0.000 claims 1
- 201000008450 Intracranial aneurysm Diseases 0.000 claims 1
- 108010001014 Plasminogen Activators Proteins 0.000 claims 1
- 102000001938 Plasminogen Activators Human genes 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 230000002490 cerebral effect Effects 0.000 claims 1
- 238000003384 imaging method Methods 0.000 claims 1
- 230000007574 infarction Effects 0.000 claims 1
- 230000036244 malformation Effects 0.000 claims 1
- 208000018389 neoplasm of cerebral hemisphere Diseases 0.000 claims 1
- 229940127126 plasminogen activator Drugs 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/49—Urokinase; Tissue plasminogen activator
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Magnetic Resonance Imaging Apparatus (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Electrotherapy Devices (AREA)
- Saccharide Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Claims (10)
1. Dezmoteplaza za uporabu u liječenju pacijenata s moždanim udarom, pri čemu je pacijent prije liječenja odabran prema izražavanju sljedećih kriterija kod prijama
a. ugroženo cerebralno tkivo
b. okluzija cerebralnih areterija
c. NIHSS bodovi od najmanje 4, i
d. stenoza visokog stupnja, karakterizirana TIMI ststusom 0 ili 1.
2. Dezmoteplaza za uporabu u skladu s patentnim zahtjevom 1 gdje je okluzija cerebralne arterije ili stenoza visokog stupnja kod pacijenta s moždanim udarom lokalizirana u MCA, ACA ili PCA ili njihovim ograncima.
3. Dezmoteplaza za uporabu u skladu s patentnim zahtjevom 2 gdje je okluzija cerebralne arterije ili stenoza visokog stupnja kod pacijenta s moždanim udarom lokalizirana u ogranku M1 ili M2 u MCA, ACA ili PCA.
4. Dezmoteplaza za uporabu u skladu s jednim od prethodnih patentnih zahtjeva, gdjeje okluzija arterije kod pacijenta s moždanim udarom TIMI 0 ili 1.
5. Dezmoteplaza za uporabu u skladu s jednim od prethodnih patentnih zahtjeva, gdje je ugroženo tkivo pacijenta s moždanim udarom lokalizirano u području MCA, ACA ili PCA.
6. Dezmoteplaza za uporabu u skladu s jednim od prethodnih patentnih zahtjeva, gdje pacijent prikazuje moždani udar NIHSS bodova od najmanje 8, poželjno između 8 i 24 (uključujući).
7. Dezmoteplaza za uporabu u skladu s jednim od prethodnih patentnih zahtjeva, gdje je okluzija arterije i/ili ugroženo tkivo pacijenta s moždanim udarom procijenjeno prije liječenja individualno slikovnom tehnikom.
8. Dezmoteplaza za uporabu u skladu s jednim ili više od prethodnih patentnih zahtjeva, gdje je pacijent nadalje karakteriziran jednim ili više od sljedećih svojstava kod prijama:
a. akutni infarkt ne obuhvaća više od oko 1/3 MCA ili sadržajno cijelo ACA ili PCA područje i/ili
b. odsutnost ICH, SAH, AV malformacije, cerebralne aneurizme ili cerebralne neoplazme.
9. Dezmoteplaza za uporabu u skladu s jednim ili više od prethodnih patentnih zahtjeva, gdje je aktivator plazminogena dan pacijentu u dozi od oko 90 do oko 125 µg/kg tjelesne težine, posebno oko 90 ili oko 125 µg/kg tjelesne težine.
10. Dezmoteplaza za uporabu u skladu s jednim ili više od prethodnih patentnih zahtjeva, pri čemu je pacijent liječen nakon više od 3 sata nakon nastupa moždanog udara ili unutar 3 do 9 sati nakon nastupa simptoma moždanog udara.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07020401A EP2050462A1 (en) | 2007-10-18 | 2007-10-18 | Improved treatment of stroke patients |
| EP07022867 | 2007-11-26 | ||
| EP08017954 | 2008-10-15 | ||
| EP08838897.0A EP2211898B1 (en) | 2007-10-18 | 2008-10-20 | Novel patient subgroups for thrombolysis |
| PCT/EP2008/008871 WO2009049914A2 (en) | 2007-10-18 | 2008-10-20 | Novel patient subgroups for thrombolysis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20170001T1 true HRP20170001T1 (hr) | 2017-02-24 |
Family
ID=40567844
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20170001TT HRP20170001T1 (hr) | 2007-10-18 | 2017-01-03 | Nove podgrupe pacijenata za trombolizu |
Country Status (29)
| Country | Link |
|---|---|
| US (2) | US20100272704A1 (hr) |
| EP (1) | EP2211898B1 (hr) |
| JP (2) | JP5509085B2 (hr) |
| KR (1) | KR20100089077A (hr) |
| CN (1) | CN101903039B (hr) |
| AR (1) | AR068914A1 (hr) |
| AU (1) | AU2008314048B2 (hr) |
| BR (1) | BRPI0817785A2 (hr) |
| CA (1) | CA2702378A1 (hr) |
| CL (1) | CL2009000752A1 (hr) |
| CY (1) | CY1118417T1 (hr) |
| DK (1) | DK2211898T3 (hr) |
| EA (1) | EA020776B1 (hr) |
| ES (1) | ES2611155T3 (hr) |
| HK (1) | HK1151233A1 (hr) |
| HR (1) | HRP20170001T1 (hr) |
| HU (1) | HUE032867T2 (hr) |
| IL (1) | IL205175A0 (hr) |
| LT (1) | LT2211898T (hr) |
| MX (1) | MX2010004157A (hr) |
| MY (1) | MY159200A (hr) |
| NZ (1) | NZ584640A (hr) |
| PL (1) | PL2211898T3 (hr) |
| PT (1) | PT2211898T (hr) |
| RS (1) | RS55590B1 (hr) |
| SI (1) | SI2211898T1 (hr) |
| TW (1) | TWI482628B (hr) |
| WO (1) | WO2009049914A2 (hr) |
| ZA (1) | ZA201002548B (hr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10153601A1 (de) * | 2001-11-02 | 2003-05-22 | Paion Gmbh | DSPA zur Behandlung von Schlaganfall |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4766075A (en) * | 1982-07-14 | 1988-08-23 | Genentech, Inc. | Human tissue plasminogen activator |
| US5244806A (en) * | 1985-08-26 | 1993-09-14 | Eli Lilly And Company | DNA encoding novel tissue plasminogen activator derivatives having kringles 1 and 2 deleted, vectors and host cells |
| IL87276A (en) * | 1987-08-03 | 1995-07-31 | Fujisawa Pharmaceutical Co | Analog of a tissue plasminogen activator containing the Pringle 2 and protease regions only, DNA encoding it, processes for its preparation, and pharmaceutical preparations containing it |
| US5094953A (en) * | 1988-03-21 | 1992-03-10 | Genentech, Inc. | Human tissue plasminogen activator variants |
| FI100403B (fi) * | 1988-07-20 | 1997-11-28 | Schering Ag | Menetelmä glykosyloitujen tai glykosyloimattomien vampyyrilepakon sylj en plasminogeeniaktivaattoreiden valmistamiseksi |
| US5714145A (en) * | 1988-09-02 | 1998-02-03 | Genentech, Inc. | Tissue plasminogen activator having zymogenic or fibrin specific properties |
| US5676947A (en) * | 1989-02-07 | 1997-10-14 | Boehringer Manneheim Gmbh | Method for treating thromboembolic conditions using thrombolytically active proteins |
| DE3903581A1 (de) * | 1989-02-07 | 1990-08-16 | Boehringer Mannheim Gmbh | Gewebs-plasminogenaktivator-derivat |
| US6008019A (en) * | 1989-02-13 | 1999-12-28 | Schering Aktiengesellschaft | Plasminogen activator from saliva of the vampire bat |
| US5891664A (en) * | 1989-04-07 | 1999-04-06 | Cancerforskningsfondet Af 1989 | Vectors and methods for recombinant production of uPA-binding fragments of the human urokinase-type plasminogen receptor (uPAR) |
| US5326700A (en) * | 1990-11-06 | 1994-07-05 | Eli Lilly And Company | DNA sequences encoding t-PA derivatives with cleavable sites |
| WO1992018157A1 (de) * | 1991-04-16 | 1992-10-29 | Boehringer Mannheim Gmbh | Pharmazeutische verpackungseinheit enthaltend plasminogenaktivatoren zur mehrfachbolusgabe |
| US5595736A (en) * | 1991-04-22 | 1997-01-21 | Eli Lilly And Company | Compounds and methods for treatment of thromboembolic disorders |
| RU2183214C2 (ru) * | 1992-12-04 | 2002-06-10 | Шеринг Аг | Природный и рекомбинантный ингибиторы тромбина, их получение и применение |
| US5510330A (en) * | 1994-03-25 | 1996-04-23 | Boehringer Mannheim Gmbh | Combinations of thrombolytically active proteins and non-heparin anticoagulants, and uses thereof. |
| GB9412131D0 (en) * | 1994-06-17 | 1994-08-10 | British Bio Technology | Thrombolytic composition |
| US5827832A (en) * | 1995-03-06 | 1998-10-27 | Interneuron Pharmaceuticals, Inc. | Method of protecting brain tissue from cerebral infarction subsequent to ischemia |
| US5786187A (en) * | 1995-09-21 | 1998-07-28 | The Research Foundation Of State University Of New York | Method for reducing neuronal degeneration associated with seizure |
| US5945432A (en) * | 1995-12-22 | 1999-08-31 | The University Of Vermont And State Agricultural College | Thrombolytic agents and thienopyridine derivatives in acute stroke |
| US20020081294A1 (en) * | 1996-01-23 | 2002-06-27 | Genentech, Inc. | Co-administration of a thrombolytic and an anti-CD18 antibody in stroke |
| US5731186A (en) * | 1996-02-05 | 1998-03-24 | Schering Aktiengesellschaft | Method for the production of rDSPA α1 |
| US6354999B1 (en) * | 2000-01-14 | 2002-03-12 | Florence Medical Ltd. | System and method for detecting, localizing, and characterizing occlusions and aneurysms in a vessel |
| GB0025473D0 (en) * | 2000-10-17 | 2000-11-29 | Pfizer Ltd | Pharmaceutical combinations |
| DE10153601A1 (de) * | 2001-11-02 | 2003-05-22 | Paion Gmbh | DSPA zur Behandlung von Schlaganfall |
| US20080057050A1 (en) * | 2003-05-02 | 2008-03-06 | Paion Deutschland Gmbh | Intravenous injection of plasminogen non-neurotoxic activators for treating cerebral stroke |
| US20060135425A1 (en) * | 2003-05-02 | 2006-06-22 | Paion Deutschland Gmbh | Intravenous injection of plasminogen non-neurotoxic activators for treating cerebral stroke |
| CA2524342A1 (en) * | 2003-05-05 | 2004-11-18 | Paion Deutschland Gmbh | Glutamate receptor antagonists as neuroprotectives |
| WO2005018564A2 (en) * | 2003-08-22 | 2005-03-03 | Pharmacia Corporation | Compositions of a cyclooxygenase-2 selective inhibitor and a low-molecular-weight heparin for the treatment of central nervous system damage |
| AU2006282856A1 (en) * | 2005-08-25 | 2007-03-01 | Biogen Idec Ma Inc. | Nogo receptor polypeptides and polypeptide fragments and uses thereof |
-
2008
- 2008-10-17 TW TW097139886A patent/TWI482628B/zh not_active IP Right Cessation
- 2008-10-17 AR ARP080104540A patent/AR068914A1/es unknown
- 2008-10-20 LT LTEP08838897.0T patent/LT2211898T/lt unknown
- 2008-10-20 ES ES08838897.0T patent/ES2611155T3/es active Active
- 2008-10-20 JP JP2010529300A patent/JP5509085B2/ja not_active Expired - Fee Related
- 2008-10-20 WO PCT/EP2008/008871 patent/WO2009049914A2/en active Application Filing
- 2008-10-20 EP EP08838897.0A patent/EP2211898B1/en active Active
- 2008-10-20 AU AU2008314048A patent/AU2008314048B2/en not_active Ceased
- 2008-10-20 CN CN200880112073.2A patent/CN101903039B/zh not_active Expired - Fee Related
- 2008-10-20 RS RS20170031A patent/RS55590B1/sr unknown
- 2008-10-20 PT PT88388970T patent/PT2211898T/pt unknown
- 2008-10-20 NZ NZ584640A patent/NZ584640A/xx not_active IP Right Cessation
- 2008-10-20 MY MYPI2010001704A patent/MY159200A/en unknown
- 2008-10-20 US US12/682,779 patent/US20100272704A1/en not_active Abandoned
- 2008-10-20 PL PL08838897T patent/PL2211898T3/pl unknown
- 2008-10-20 DK DK08838897.0T patent/DK2211898T3/en active
- 2008-10-20 EA EA201070485A patent/EA020776B1/ru not_active IP Right Cessation
- 2008-10-20 KR KR1020107010609A patent/KR20100089077A/ko active Search and Examination
- 2008-10-20 SI SI200831750A patent/SI2211898T1/sl unknown
- 2008-10-20 CA CA2702378A patent/CA2702378A1/en not_active Abandoned
- 2008-10-20 HU HUE08838897A patent/HUE032867T2/en unknown
- 2008-10-20 MX MX2010004157A patent/MX2010004157A/es active IP Right Grant
- 2008-10-20 BR BRPI0817785-6A patent/BRPI0817785A2/pt not_active IP Right Cessation
-
2009
- 2009-03-27 CL CL2009000752A patent/CL2009000752A1/es unknown
-
2010
- 2010-04-12 ZA ZA2010/02548A patent/ZA201002548B/en unknown
- 2010-04-18 IL IL205175A patent/IL205175A0/en unknown
-
2011
- 2011-05-30 HK HK11105336.9A patent/HK1151233A1/xx not_active IP Right Cessation
-
2014
- 2014-01-07 JP JP2014000825A patent/JP2014065739A/ja not_active Withdrawn
- 2014-02-14 US US14/181,153 patent/US20140314736A1/en not_active Abandoned
-
2017
- 2017-01-03 HR HRP20170001TT patent/HRP20170001T1/hr unknown
- 2017-01-11 CY CY20171100041T patent/CY1118417T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Chimowitz | Endovascular treatment for acute ischemic stroke—still unproven | |
| Sankar et al. | Evaluation of the efficacy of tranexamic acid on blood loss in orthognathic surgery. A prospective, randomized clinical study | |
| Raza et al. | Extracorporeal shockwave therapy for peripheral arterial disease: a review of the potential mechanisms of action | |
| Chew et al. | Update of the ACCORD eye study | |
| Yang | Antiplatelet therapy following percutaneous coronary intervention in patients complicated by COVID-19: implications from clinical features to pathological findings | |
| HRP20170001T1 (hr) | Nove podgrupe pacijenata za trombolizu | |
| Tajiri et al. | Cerebral aneurysm as an exacerbating factor in stroke pathology and a therapeutic target for neuroprotection | |
| Danik et al. | Anticoagulation in pregnant women with prosthetic heart valves. | |
| Klevanets et al. | Systemic thrombolytic therapy and catheter-directed fragmentation with local thrombolytic therapy in patients with pulmonary embolism | |
| Tapson et al. | Optimum duration and dose of r-tPA with the acoustic pulse thrombolysis procedure for intermediate-risk (submassive) pulmonary embolism: OPTALYSE PE | |
| Kim et al. | Case of Deep Vein Thrombosis Patient Treated by Korean Medicine | |
| Wang et al. | Successful treatment with recombinant blood factor VIIa in severe postpartum hemorrhage-induced disseminated intravascular coagulation | |
| Panova et al. | Synthesis of the matrix metalloproteinases and its inhibitors by peripheral blood phagocytes of women with hypertansion disorders | |
| Poliwoda | Treatment of chronic arterial occlusions with streptokinase. | |
| JP2017508768A5 (hr) | ||
| RU2548739C1 (ru) | Способ лечения реперфузионного синдрома у больных сахарным диабетом после реваскуляризирующих операций на артериях нижних конечностей | |
| Cohen et al. | Major Stroke After Spontaneous Carotid Artery Dissection with Associated Thrombus in a Patient with COVID-19: Carotid Angioplasty, Clot Aspiration Under Balloon Guiding Catheter-Assisted Flow Arrest, Stenting, and Mechanical Thrombectomy; Is COVID-19 a Risk Factor for Carotid Dissection and Stroke? | |
| Elaggory et al. | Anticoagulation alone versus combined catheter-directed thrombolysis and anticoagulation in treatment of acute ilio-femoral deep venous thrombosis | |
| Vatsa et al. | Hemangioma of lower lip: A case report | |
| Sran et al. | The role of interferon in premature atherosclerosis in systemic lupus erythematosus patients | |
| Gnanaraj et al. | PO311 Sailing Through Pregnancy With a Prosthetic Heart Valve | |
| Krivoschekov et al. | Acute varicotrombomphlebitis: treatment with oral subtilisins | |
| Mastrandrea et al. | The detrimental effects of bedrest: Premature cardiovascular aging and dysfunction | |
| Galvin | Hematologic and Immune Symptoms | |
| Sosa et al. | LETTER TO THE EDITOR–not commissioned |